Drug Interactions between dicumarol and Opdivo Qvantig
This report displays the potential drug interactions for the following 2 drugs:
- dicumarol
- Opdivo Qvantig (hyaluronidase/nivolumab)
Interactions between your drugs
dicumarol nivolumab
Applies to: dicumarol and Opdivo Qvantig (hyaluronidase / nivolumab)
Consumer information for this interaction is not currently available.
MONITOR: Use of vitamin K antagonists concurrently with immune checkpoint inhibitors (ICIs) such as anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 monoclonal antibodies and/or inhibitors of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) may result in enhanced anticoagulant effects of vitamin K antagonists. The proposed mechanism of this interaction has not been fully investigated, but may involve hepatic and thyroid dysfunction induced by ICIs, resulting in reduced production of coagulation factors and lower albumin levels, which could lead to an increase in prothrombin time-to-international normalized ratio (PT-INR). Clinical evidence of this interaction is limited. In a retrospective single-arm cohort study involving 26 cancer patients on stable doses of warfarin, 21 of those patients had an elevated PT-INR within 60 days of starting an ICI (pembrolizumab, nivolumab, atezolizumab, or ipilimumab). Thirteen of those patients had an increase in PT-INR of more than 1.5- fold, with 5 of them requiring immediate administration of vitamin K.
MANAGEMENT: Until more information is available, clinical and laboratory monitoring for increased anticoagulant effects is advised if therapy with a vitamin K antagonist and ICI are required. Alternative treatments or dosage adjustments may be required if an interaction is suspected. Patients should be advised to notify their doctor if they develop signs and symptoms of excessive anticoagulation, such as unusual or prolonged bleeding, bruising, vomiting, change in stool or urine color, headache, dizziness, or weakness.
Drug and food interactions
dicumarol food
Applies to: dicumarol
Nutrition and diet can affect your treatment with dicumarol. Therefore, it is important to keep your vitamin supplement and food intake steady throughout treatment. For example, increasing vitamin K levels in the body can promote clotting and reduce the effectiveness of dicumarol. While there is no need to avoid products that contain vitamin K, you should maintain a consistent level of consumption of these products. Foods rich in vitamin K include beef liver, broccoli, Brussels sprouts, cabbage, collard greens, endive, kale, lettuce, mustard greens, parsley, soy beans, spinach, Swiss chard, turnip greens, watercress, and other green leafy vegetables. Moderate to high levels of vitamin K are also found in other foods such as asparagus, avocados, dill pickles, green peas, green tea, canola oil, margarine, mayonnaise, olive oil, and soybean oil. However, even foods that do not contain much vitamin K may occasionally affect the action of dicumarol. There have been reports of patients who experienced bleeding complications and increased INR or bleeding times after consuming large quantities of cranberry juice, mangos, grapefruit, grapefruit juice, grapefruit seed extract, or pomegranate juice. Again, you do not need to avoid these foods completely, but it may be preferable to limit their consumption, or at least maintain the same level of use while you are receiving dicumarol. Talk to a healthcare provider if you are uncertain about what foods or medications you take that may interact with dicumarol. It is important to tell your doctor about all medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
When dicumarol is given with enteral (tube) feedings, you may interrupt the feeding for one hour before and one hour after the dicumarol dose to minimize potential for interaction. Feeding formulas containing soy protein should be avoided.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.